HCPLive

Long-Acting Clotting Agent Approved for Form of Hemophilia

MONDAY, March 31, 2014 (HealthDay News) -- The drug Alprolix has been approved by the US Food and Drug Administration (FDA) as the first long-acting hemophilia B clotting agent, the FDA said in a news release.

The product, formally known as "coagulation factor IX recombinant Fc Fusion protein" is the first hemophilia B remedy designed to require less frequent injections than prior treatments, the FDA said. It was approved to help control and prevent bleeding episodes and to manage bleeding during surgery.

Alprolix was evaluated in clinical studies involving 123 people, ages 12-71, with severe hemophilia B. No safety issues were identified during the trials, the FDA said.

The product is manufactured by Biogen Idec, located in Cambridge, Mass.

More Information


Copyright © 2014 HealthDay. All rights reserved.

Most Popular

Recommended Reading

Another investigational diabetes drug appears to have promise for patients with nonalcoholic steatohepatitis, researchers reported at the International Liver Congress in Vienna, Austria.
The explosion in new drugs to treat hepatitis C is leading to predictions the viral infection will no longer be a major health problem. But before that can happen, much has to be done in the realm of public health, researchers said April 25 at the International Liver Congress in Vienna, Austria.
In addition to injection drug use, alcohol consumption puts people at risk of dying from hepatitis C infection by increasin the severity of the disease. A French research study spells out the risks.
Natalizumab, a drug typically used to treat multiple sclerosis and Crohn’s disease, has been shown to be effective in treating animal models of HIV.
$vAR$